Variations in the 3′UTR of the CYP21A2 Gene in Heterozygous Females with Hyperandrogenaemia

Heterozygosity for CYP21A2 mutations in females is possibly related to increased risk of developing clinical hyperandrogenism. The present study was designed to seek evidence on the phenotype-genotype correlation in female children, adolescents, and women with CYP21A2 mutations and variants in the 3...

Full description

Saved in:
Bibliographic Details
Main Authors: Vassos Neocleous, Pavlos Fanis, Meropi Toumba, Alexia A. P. Phedonos, Michalis Picolos, Elena Andreou, Tassos C. Kyriakides, George A. Tanteles, Christos Shammas, Leonidas A. Phylactou, Nicos Skordis
Format: Article
Language:English
Published: Wiley 2017-01-01
Series:International Journal of Endocrinology
Online Access:http://dx.doi.org/10.1155/2017/8984365
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849400147355631616
author Vassos Neocleous
Pavlos Fanis
Meropi Toumba
Alexia A. P. Phedonos
Michalis Picolos
Elena Andreou
Tassos C. Kyriakides
George A. Tanteles
Christos Shammas
Leonidas A. Phylactou
Nicos Skordis
author_facet Vassos Neocleous
Pavlos Fanis
Meropi Toumba
Alexia A. P. Phedonos
Michalis Picolos
Elena Andreou
Tassos C. Kyriakides
George A. Tanteles
Christos Shammas
Leonidas A. Phylactou
Nicos Skordis
author_sort Vassos Neocleous
collection DOAJ
description Heterozygosity for CYP21A2 mutations in females is possibly related to increased risk of developing clinical hyperandrogenism. The present study was designed to seek evidence on the phenotype-genotype correlation in female children, adolescents, and women with CYP21A2 mutations and variants in the 3′UTR region of the gene. Sixty-six patients out of the 169 were identified as carriers of CYP21A2 mutations. Higher values of stimulated 17 hydroxyprogesterone (17-OHP) levels were found in the carriers of the p.Val281Leu mutation compared to the carriers of other mutations (mean: 24.7 nmol/l versus 15.6 nmol/l). The haplotype of the ∗52C>T, ∗440C>T, and ∗443T>C in the 3′UTR was identical in all heterozygous patients with p.Val281Leu and the haplotype of the ∗12C>T and ∗52C>T was identical in all heterozygous patients with the p.Gln318∗. In conclusion, hyperandrogenaemic females are likely to bear heterozygous CYP21A2 mutations. Carriers of the mild p.Val281Leu mutation are at higher risk of developing hyperandrogenism than the carriers of more severe mutations. The identification of variants in the 3′UTR of CYP21A2 in combination with the heterozygous mutation may be associated with the mild form of nonclassic congenital adrenal hyperplasia and reveal the importance of analyzing the CYP21A2 untranslated regions for the appropriate management of this category of patients.
format Article
id doaj-art-a06836efd0164039ab1a9291f37ebb7a
institution Kabale University
issn 1687-8337
1687-8345
language English
publishDate 2017-01-01
publisher Wiley
record_format Article
series International Journal of Endocrinology
spelling doaj-art-a06836efd0164039ab1a9291f37ebb7a2025-08-20T03:38:09ZengWileyInternational Journal of Endocrinology1687-83371687-83452017-01-01201710.1155/2017/89843658984365Variations in the 3′UTR of the CYP21A2 Gene in Heterozygous Females with HyperandrogenaemiaVassos Neocleous0Pavlos Fanis1Meropi Toumba2Alexia A. P. Phedonos3Michalis Picolos4Elena Andreou5Tassos C. Kyriakides6George A. Tanteles7Christos Shammas8Leonidas A. Phylactou9Nicos Skordis10Department of Molecular Genetics, Function & Therapy, The Cyprus Institute of Neurology & Genetics, Nicosia, CyprusDepartment of Molecular Genetics, Function & Therapy, The Cyprus Institute of Neurology & Genetics, Nicosia, CyprusDepartment of Molecular Genetics, Function & Therapy, The Cyprus Institute of Neurology & Genetics, Nicosia, CyprusDepartment of Molecular Genetics, Function & Therapy, The Cyprus Institute of Neurology & Genetics, Nicosia, CyprusAlithias Endocrinology Center, Nicosia, CyprusDasoupolis Endocrinology Center, Andrea Dimitriou Street Dasoupolis, Nicosia, CyprusYale Center for Analytical Sciences, Yale School of Public Health, New Haven, CT, USAClinical Genetics Department, The Cyprus Institute of Neurology & Genetics, Nicosia, CyprusDepartment of Molecular Genetics, Function & Therapy, The Cyprus Institute of Neurology & Genetics, Nicosia, CyprusDepartment of Molecular Genetics, Function & Therapy, The Cyprus Institute of Neurology & Genetics, Nicosia, CyprusDepartment of Molecular Genetics, Function & Therapy, The Cyprus Institute of Neurology & Genetics, Nicosia, CyprusHeterozygosity for CYP21A2 mutations in females is possibly related to increased risk of developing clinical hyperandrogenism. The present study was designed to seek evidence on the phenotype-genotype correlation in female children, adolescents, and women with CYP21A2 mutations and variants in the 3′UTR region of the gene. Sixty-six patients out of the 169 were identified as carriers of CYP21A2 mutations. Higher values of stimulated 17 hydroxyprogesterone (17-OHP) levels were found in the carriers of the p.Val281Leu mutation compared to the carriers of other mutations (mean: 24.7 nmol/l versus 15.6 nmol/l). The haplotype of the ∗52C>T, ∗440C>T, and ∗443T>C in the 3′UTR was identical in all heterozygous patients with p.Val281Leu and the haplotype of the ∗12C>T and ∗52C>T was identical in all heterozygous patients with the p.Gln318∗. In conclusion, hyperandrogenaemic females are likely to bear heterozygous CYP21A2 mutations. Carriers of the mild p.Val281Leu mutation are at higher risk of developing hyperandrogenism than the carriers of more severe mutations. The identification of variants in the 3′UTR of CYP21A2 in combination with the heterozygous mutation may be associated with the mild form of nonclassic congenital adrenal hyperplasia and reveal the importance of analyzing the CYP21A2 untranslated regions for the appropriate management of this category of patients.http://dx.doi.org/10.1155/2017/8984365
spellingShingle Vassos Neocleous
Pavlos Fanis
Meropi Toumba
Alexia A. P. Phedonos
Michalis Picolos
Elena Andreou
Tassos C. Kyriakides
George A. Tanteles
Christos Shammas
Leonidas A. Phylactou
Nicos Skordis
Variations in the 3′UTR of the CYP21A2 Gene in Heterozygous Females with Hyperandrogenaemia
International Journal of Endocrinology
title Variations in the 3′UTR of the CYP21A2 Gene in Heterozygous Females with Hyperandrogenaemia
title_full Variations in the 3′UTR of the CYP21A2 Gene in Heterozygous Females with Hyperandrogenaemia
title_fullStr Variations in the 3′UTR of the CYP21A2 Gene in Heterozygous Females with Hyperandrogenaemia
title_full_unstemmed Variations in the 3′UTR of the CYP21A2 Gene in Heterozygous Females with Hyperandrogenaemia
title_short Variations in the 3′UTR of the CYP21A2 Gene in Heterozygous Females with Hyperandrogenaemia
title_sort variations in the 3 utr of the cyp21a2 gene in heterozygous females with hyperandrogenaemia
url http://dx.doi.org/10.1155/2017/8984365
work_keys_str_mv AT vassosneocleous variationsinthe3utrofthecyp21a2geneinheterozygousfemaleswithhyperandrogenaemia
AT pavlosfanis variationsinthe3utrofthecyp21a2geneinheterozygousfemaleswithhyperandrogenaemia
AT meropitoumba variationsinthe3utrofthecyp21a2geneinheterozygousfemaleswithhyperandrogenaemia
AT alexiaapphedonos variationsinthe3utrofthecyp21a2geneinheterozygousfemaleswithhyperandrogenaemia
AT michalispicolos variationsinthe3utrofthecyp21a2geneinheterozygousfemaleswithhyperandrogenaemia
AT elenaandreou variationsinthe3utrofthecyp21a2geneinheterozygousfemaleswithhyperandrogenaemia
AT tassosckyriakides variationsinthe3utrofthecyp21a2geneinheterozygousfemaleswithhyperandrogenaemia
AT georgeatanteles variationsinthe3utrofthecyp21a2geneinheterozygousfemaleswithhyperandrogenaemia
AT christosshammas variationsinthe3utrofthecyp21a2geneinheterozygousfemaleswithhyperandrogenaemia
AT leonidasaphylactou variationsinthe3utrofthecyp21a2geneinheterozygousfemaleswithhyperandrogenaemia
AT nicosskordis variationsinthe3utrofthecyp21a2geneinheterozygousfemaleswithhyperandrogenaemia